- Home
- BHC
as 10-15-2025 4:00pm EST
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
| Founded: | N/A | Country: | Canada |
| Employees: | N/A | City: | QUEBEC |
| Market Cap: | 2.2B | IPO Year: | N/A |
| Target Price: | $9.00 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.25 - $9.85 | Next Earning Date: | 10-29-2025 |
| Revenue: | $9,858,000,000 | Revenue Growth: | 7.13% |
| Revenue Growth (this year): | 6.28% | Revenue Growth (next year): | 3.76% |
Stock Insider Trading Activity of Bausch Health Companies Inc. (BHC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Carson Seana | BHC | EVP, General Counsel | Sep 8 '25 | Sell | $7.31 | 13,370 | $97,734.70 | 499,585 | |
| Lee Frank D. | BHC | N/A | Aug 21 '25 | Sell | $7.66 | 15,912 | $121,885.92 | 73,795 | |
| Paulson John | BHC | N/A | Aug 14 '25 | Buy | $9.00 | 34,721,118 | $312,490,062.00 | 70,755,869 | |
| Paulson John | BHC | N/A | Aug 13 '25 | Buy | $7.06 | 86,409 | $610,047.54 | 70,755,869 | |
| Paulson John | BHC | N/A | Aug 12 '25 | Buy | $6.88 | 1,156,640 | $7,957,683.20 | 70,755,869 | |
| Paulson John | BHC | N/A | Aug 11 '25 | Buy | $6.35 | 2,000,000 | $12,700,000.00 | 70,755,869 |
Latest Bausch Health Companies Inc. News
BHC Breaking Stock News: Dive into BHC Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 days ago
George Medicines strengthens global commercialization strategy for GMRx2 with exclusive Biolab Farmacêutica licensing agreement in Brazil
ACCESS Newswire
16 days ago
Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV
ACCESS Newswire
16 days ago
Bausch Health to Announce Third Quarter 2025 Results on October 29
ACCESS Newswire
17 days ago
Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to Dentistry
MT Newswires
a month ago
Bausch Health Completes US$63 Million Durect Acquisition, Adds Breakthrough Hepatitis Therapy to Pipeline
MT Newswires
a month ago
Bausch Health Completes $63 Million Acquisition of Durect
PR Newswire
a month ago
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
Simply Wall St.
a month ago
Bausch Health (NYSE:BHC): Revisiting Valuation After Recent Share Price Momentum
Compare BHC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BHC Bausch Health Companies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.